| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22009 |
| Drug |
Avacopan |
| Brand |
Tavneos® |
| Indication |
In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic polyangiitis. |
| Rapid review commissioned |
14/02/2022 |
| Rapid review completed |
08/03/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avacopan (Tavneos®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/04/2022 |
| Pre-submission consultation with Applicant |
21/06/2022 |
| Full submission received from Applicant |
19/10/2022 |
